恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

交易中 07-08 11:18:58

59.750

+0.050

+0.08%

最高62.000	最低59.700	成交量179.17万
今开60.100	昨收59.700	日振幅3.85%
总市值3,966亿	流通市值154.16亿	总股本66.37亿
成交额1.08亿	换手率0.69%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":59.75,"timestamp":1783480727816,"preClose":59.7,"halted":0,"volume":1791700,"delay":0,"changeRate":0.0008375209380234029,"floatShares":258000000,"shares":6637000000,"eps":1.360436623694363,"marketStatus":"交易中","change":0.05,"latestTime":"07-08 11:18:58","open":60.1,"high":62,"low":59.7,"amount":108478653,"amplitude":0.038526,"askPrice":59.75,"askSize":16400,"bidPrice":59.7,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":1.4073809105109625,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1783483200000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":59.7,"dividendRate":0.003878,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":1.152275,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.32,"timestamp":1783480735000,"preClose":55.36,"halted":0,"volume":66927300,"delay":0,"premium":"-4.59"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"1137840609","title":"异动解读｜恒瑞医药盘中上涨3.6%，自研创新抗肿瘤药SHR-4685获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137840609","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137840609?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:52","pubTimestamp":1783475574,"startTime":"0","endTime":"0","summary":"7月8日，恒瑞医药盘中上涨3.6%，报61.5港元，成交额6029.77万港元。消息面上，公司7月7日晚间公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局核准签发的SHR-4685注射液《药物临床试验批准通知书》，同意该品种单药在晚期实体瘤中开展临床试验。该药物为公司自主研发的创新型抗肿瘤药物，目前国内外尚无同类药物获批上市，项目累计研发投入约1940万元。同期制药板块整体走强，中国生物制药涨6.22%，翰森制药涨3.07%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153230886","title":"恒瑞医药（01276）获批开展SHR-4685注射液晚期实体瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1153230886","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153230886?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:39","pubTimestamp":1783427984,"startTime":"0","endTime":"0","summary":"2026年7月7日，恒瑞医药（01276）公告称，其子公司苏州盛迪亚生物医药有限公司已收到国家药品监督管理局于2026年4月9日受理的SHR-4685注射液《药物临床试验批准通知书》，批准该产品作为单药用于晚期实体瘤的临床试验。\nSHR-4685注射液为公司自主研发的创新抗肿瘤药物，目前国内外尚无同类药物获批上市。公告显示，截至目前，该项目累计研发投入约为1,940万元（未经审计）。\n公司提示，药物上市仍需完成临床试验并通过后续审评审批，研发和上市周期较长，存在不确定性风险。恒瑞医药表示，将按国家相关规定推进项目进展，并及时披露相关信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649898554","title":"恒瑞医药：子公司SHR-4685注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2649898554","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649898554?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:10","pubTimestamp":1783415400,"startTime":"0","endTime":"0","summary":"7月7日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607073796801870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","LU1969619763.USD","LU1064131003.USD","LU2097828557.USD","BK0188","LU0359201612.USD","01276","600276","LU2148510915.USD","LU1255011170.USD","LU2097828805.USD","LU1655091616.SGD","BK0060","LU1328615791.USD","LU2289578879.USD","LU2580892789.USD","LU1820825898.SGD","LU1781817850.SGD","IBBQ","BK0183","LU2488822045.USD","LU1023057109.AUD","BK0028","LU2097828714.EUR","BK0239","BK0196","LU0359201885.HKD","LU2328871848.SGD","LU0359202008.SGD","LU1580142542.USD","LU1997245177.USD","LU2543165471.USD","LU0405327148.USD","BMED","LU2097828474.EUR","LU2097828631.EUR","LU2580892862.HKD","LU1997244956.HKD","BK1191","BK0012","LU1064130708.USD","LU1997245094.SGD","LU0405327494.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649562670","title":"“老登”股上涨，要变盘了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2649562670","media":"投资人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649562670?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:43","pubTimestamp":1783334580,"startTime":"0","endTime":"0","summary":"创新药引领生物医药板块的上涨，恒瑞医药、康龙化成、百济神州均大涨了3%以上。其他消费股也有所上涨，贵州茅台上涨了1.04%，伊利股份上涨了1.91%。　　最近这段时间，确实一个比较关键的时间点，已经出现了几次这种“老登”股上涨，AI科技跌的行情，资金在不断试探市场的反应，市场或许正要迎来变盘，风格或许真的要变了。　　而“老登”股的情况却是相反，市场给予的预期已经很差了，目前也基本上在股价上体现出了。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-06/doc-inifwmvw8589195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01276","LU1023057109.AUD","LU0359201612.USD","BK1191","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649101436","title":"港股异动 | 恒瑞医药(01276.HK)涨近5% 注射用瑞康曲妥珠单抗药品上市许可申请获受理 已被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2649101436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649101436?lang=zh_cn&edition=full","pubTime":"2026-07-06 11:05","pubTimestamp":1783307136,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2543165471.USD","LU0359201612.USD","BK1191","LU1023057109.AUD","01276","LU0359202008.SGD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151971034","title":"异动解读｜恒瑞医药盘中上涨4.01%，制药板块集体走强叠加多款新药获批催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1151971034","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151971034?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:08","pubTimestamp":1783303711,"startTime":"0","endTime":"0","summary":"7月6日，恒瑞医药盘中上涨4.01%，报62.45港元，成交额1.2亿港元。同期制药板块集体走强，海西新药涨9.23%，中国生物制药涨8.65%，石药集团涨4.5%。消息面上，恒瑞医药近期迎来密集催化：子公司注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评；SHR-8068联合阿得贝利单抗、贝伐珠单抗治疗不可根治肝细胞癌的III期临床获批；此外，公司自研PD-L1抑制剂艾瑞利新增非小细胞肺癌围术期适应症获批，成为国内首个获批该适应症的国产PD-L1抑制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648665020","title":"恒瑞医药：公司将持续优化税务合规管理体系，坚守经营合规底线","url":"https://stock-news.laohu8.com/highlight/detail?id=2648665020","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648665020?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:00","pubTimestamp":1783080000,"startTime":"0","endTime":"0","summary":"证券日报网讯7月3日，恒瑞医药在互动平台回答投资者提问时表示，公司始终坚持合规经营、依法纳税，严格遵守国家税收法律法规，切实履行相关纳税义务。截至目前，公司不存在应披露未披露的重大税务补缴事项，公司将持续优化税务合规管理体系，坚守经营合规底线，保障企业稳健运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607033793744822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1820825898.SGD","LU1969619763.USD","LU2328871848.SGD","LU2543165471.USD","LU2488822045.USD","LU0359202008.SGD","LU2097828557.USD","LU1580142542.USD","LU0405327494.USD","LU2580892862.HKD","LU2097828714.EUR","BK0060","LU1064130708.USD","LU2097828805.USD","BK0239","LU1997245094.SGD","BK0188","LU1997244956.HKD","BK0196","BK0183","LU0405327148.USD","LU0359201612.USD","LU2495084118.USD","LU1997245177.USD","LU1328615791.USD","LU1655091616.SGD","LU1064131003.USD","LU1781817850.SGD","LU2097828631.EUR","LU0359201885.HKD","LU2097828474.EUR","01276","LU2289578879.USD","LU2580892789.USD","LU1146622755.USD","LU1023057109.AUD","LU2148510915.USD","LU1255011170.USD","BK0012","BK1191","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112564713","title":"异动解读｜恒瑞医药盘中上涨3.2%，制药板块集体走强叠加多款新药获批催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112564713","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112564713?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:46","pubTimestamp":1783043189,"startTime":"0","endTime":"0","summary":"7月3日，恒瑞医药盘中上涨3.2%，报60.55港元，成交额5079.58万港元。同期制药板块集体走强，海西新药涨7.72%，绿叶制药涨5.91%，翰森制药涨4.6%。消息面上，恒瑞医药近期迎来密集催化：子公司注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评；SHR-8068联合阿得贝利单抗、贝伐珠单抗治疗不可根治肝细胞癌的III期临床获批；此外，公司自研PD-L1抑制剂艾瑞利新增非小细胞肺癌围术期适应症获批，成为国内首个获批该适应症的国产PD-L1抑制剂。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504098","title":"恒瑞医药(01276)：截至6月30日累计回购1347.02万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504098","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648504098?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:38","pubTimestamp":1782992285,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1347.02万股，已回购股份占公司总股本的比例为0.20%，购买的最高价为人民币70.00元/股，最低价为人民币45.30元/股，已支付的总金额为人民币83799.60万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU2097828714.EUR","LU2580892789.USD","LU2097828805.USD","LU1997245177.USD","LU0359201885.HKD","LU0359201612.USD","LU1997245094.SGD","LU2289578879.USD","BK0188","399300","BK1191","LU1064131003.USD","BK0196","LU1655091616.SGD","LU2580892862.HKD","LU1781817850.SGD","BK0183","600276","LU0405327148.USD","LU2328871848.SGD","LU2097828557.USD","LU0359202008.SGD","LU2495084118.USD","LU2097828474.EUR","LU1064130708.USD","LU1820825898.SGD","01276","LU1255011170.USD","BK0060","LU1146622755.USD","LU1997244956.HKD","159982","LU0405327494.USD","LU2543165471.USD","BK0239","LU1969619763.USD","BK0012","BK0028","LU2488822045.USD","LU1328615791.USD","LU2148510915.USD","LU2097828631.EUR","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648032985","title":"恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2648032985","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648032985?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:01","pubTimestamp":1782982860,"startTime":"0","endTime":"0","summary":"7月2日，恒瑞医药（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791965633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","LU1146622755.USD","LU0405327494.USD","LU2543165471.USD","LU1969619763.USD","LU2580892789.USD","LU1820825898.SGD","LU2097828557.USD","LU2488822045.USD","LU1255011170.USD","LU2097828805.USD","600276","LU2148510915.USD","LU1023057109.AUD","LU1064130708.USD","LU2580892862.HKD","LU1328615791.USD","BK0196","LU2097828631.EUR","IPOS","BK0028","LU1997244956.HKD","LU1580142542.USD","LU0359202008.SGD","LU2289578879.USD","BK0012","BK0239","01276","LU1997245177.USD","BK0060","LU2097828474.EUR","LU2328871848.SGD","LU0405327148.USD","LU1064131003.USD","LU2097828714.EUR","BK1191","BK0183","LU1655091616.SGD","LU1781817850.SGD","LU1997245094.SGD","LU2495084118.USD","LU0359201612.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648750366","title":"恒瑞医药：SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648750366","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648750366?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:45","pubTimestamp":1782981900,"startTime":"0","endTime":"0","summary":"南财智讯7月2日电，恒瑞医药公告，SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液收到国家药品监督管理局《药物临床试验批准通知书》，同意开展抗CTLA-4抗体SHR-8068联合阿得贝利单抗、贝伐珠单抗和TACE在不可根治肝细胞癌中的随机、双盲、多中心、III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791932797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","LU1064131003.USD","BK0183","600276","LU1328615791.USD","BK0196","LU1997245177.USD","LU1064130708.USD","LU0359202008.SGD","LU2580892862.HKD","LU1146622755.USD","LU2495084118.USD","LU1969619763.USD","LU2328871848.SGD","LU1655091616.SGD","LU1023057109.AUD","LU2097828631.EUR","LU2097828714.EUR","BK0239","LU2580892789.USD","LU1997245094.SGD","LU2097828557.USD","LU2289578879.USD","LU2488822045.USD","LU2097828805.USD","LU1820825898.SGD","LU1255011170.USD","LU2097828474.EUR","LU2543165471.USD","BK0012","LU0359201612.USD","LU2148510915.USD","LU1580142542.USD","BK0028","LU0359201885.HKD","LU0405327148.USD","LU0405327494.USD","LU1781817850.SGD","BK0060","LU1997244956.HKD","BK0188","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129804302","title":"恒瑞医药发布2026年6月股份变动月报：A股回购141.4万股，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1129804302","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129804302?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:26","pubTimestamp":1782980777,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年7月2日披露了2026年6月股份变动月报表，报告期为2026年6月。在已发行股份方面，H股与上期相比无变化，仍为258,197,600股，A股则由上月的6,372,105,824股减少至6,370,691,824股，同时库藏股数量由6,896,450股增至8,310,450股，总体股本规模保持稳定。公告显示，2026年6月期间，公司多次在二级市场回购A股，回购总规模为1,414,000股，交易发生于6月4日、5日、8日、9日、10日、11日和17日，回购价格区间约为每股人民币45.62元至47.27元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648057312","title":"港股异动 | 恒瑞医药(01276)盘中涨超6% 近期创新药艾瑞利®新增适应症 国际化出海成果颇丰","url":"https://stock-news.laohu8.com/highlight/detail?id=2648057312","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648057312?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:27","pubTimestamp":1782959232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药盘中涨超6%，截至发稿，涨3.54%，报59.9港元，成交额1.36亿港元。消息面上，近日，恒瑞医药自主研发的PD-L1抑制剂艾瑞利新增适应症获国家药品监督管理局批准，用于联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切除的II、IIIA和IIIB期且无已知表皮生长因子受体突变或间变性淋巴瘤激酶重排的成人非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","BK1574","LU1064131003.USD","BK1161","BK0183","600276","LU1328615791.USD","BK0196","LU1997245177.USD","LU1064130708.USD","LU0359202008.SGD","159992","LU2580892862.HKD","LU1146622755.USD","LU2495084118.USD","LU1969619763.USD","LU2328871848.SGD","LU1655091616.SGD","LU1023057109.AUD","LU2097828631.EUR","LU2097828714.EUR","BK0239","LU2580892789.USD","LU1997245094.SGD","LU2097828557.USD","LU2289578879.USD","LU2488822045.USD","LU2097828805.USD","BK4588","LU1820825898.SGD","LU1255011170.USD","LU2097828474.EUR","LU2543165471.USD","BK0012","LU0359201612.USD","LU2148510915.USD","LU1580142542.USD","BK0028","LU0359201885.HKD","LU0405327148.USD","LU0405327494.USD","LU1781817850.SGD","BK0060","LU1997244956.HKD","BK0188","06978","BK4585","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190698502","title":"异动解读｜恒瑞医药盘中上涨3.72%，制药板块集体走强叠加多款新药获批催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1190698502","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190698502?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:35","pubTimestamp":1782956137,"startTime":"0","endTime":"0","summary":"7月2日，恒瑞医药盘中上涨3.72%，报61.8港元，成交额4246.58万港元。同期制药板块集体走强，石药集团涨超9%，中国生物制药涨超6%，翰森制药、凯莱英涨近5%。消息面上，恒瑞医药近期迎来密集催化：公司阿得贝利单抗注射液获批新增非小细胞肺癌围术期适应症，成为国内首个获批该适应症的国产PD-L1抑制剂；子公司环孢素滴眼液获上市批准；HRS-4508片获批开展晚期实体瘤临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535683","title":"智通AH统计|6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535683","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535683?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:15","pubTimestamp":1782807306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止6月30日收盘，东北电气、浙江世宝、安德利果汁分列AH溢价率前三位，溢价率分别为864.29%、377.31%、360.00%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-32.94%、-16.32%、-5.34%。其中东北电气、安德利果汁、龙蟠科技的偏离值位居前三，分别为136.07%、77.52%、56.51%；另外，弘业期货、新天绿色能源、秦港股份的偏离值位居后三，分别为-30.84%、-24.60%、-16.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02899","00390","00895","02691","EWH","02701","01349","02218","01081","01088","00916","LU0359201612.USD","03750","LU0049853897.USD","01033","03678","01276","03143","06031","01138","00719","00991","02865","LU0737861772.HKD","02338","00588","02359","02465","LU0359202008.SGD","03200","00956","00042","03986","159982","03369","01108","LU2242644610.SGD","03296","LU2045819591.USD","00300","01057","09989","03968","02208","06936","399300","LU0823426480.USD","SG9999006597.SGD","BK1151"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114419606","title":"异动解读｜恒瑞医药盘中下跌3.53%，报54.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114419606","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114419606?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:13","pubTimestamp":1782440035,"startTime":"0","endTime":"0","summary":"6月26日，恒瑞医药盘中下跌3.53%，报54.3港元/股，成交额1.14亿港元。恒瑞医药所在的制药行业中，个股表现分化，其中翰森制药涨0.14%，中国生物制药涨0.47%，石药集团涨0.6%，凯莱英涨2.21%，康哲药业跌1.38%。江苏恒瑞医药股份有限公司是一家主要从事药品研发、生产和销售的中国公司，专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物、肿瘤免疫等研究领域，产品应用于自身免疫疾病、代谢性疾病、心血管疾病等多个治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803381","title":"恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803381?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:56","pubTimestamp":1782392219,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","LU1023057109.AUD","LU2580892789.USD","LU1997244956.HKD","LU2495084118.USD","LU2488822045.USD","LU1655091616.SGD","LU0405327494.USD","LU1064130708.USD","LU1255011170.USD","LU2328871848.SGD","LU0405327148.USD","LU1064131003.USD","LU1969619763.USD","LU2097828474.EUR","BK0196","BK0239","BK0183","BK1191","BK0012","LU0359201612.USD","LU1328615791.USD","LU0359202008.SGD","LU1580142542.USD","LU2289578879.USD","BK0028","LU1146622755.USD","01276","LU2097828631.EUR","LU2097828805.USD","LU0359201885.HKD","LU1820825898.SGD","BK0060","LU1781817850.SGD","LU2148510915.USD","LU2097828714.EUR","LU2097828557.USD","LU1997245094.SGD","BK0188","LU2580892862.HKD","LU2543165471.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194506184","title":"恒瑞医药子公司获NMPA批准 艾瑞利布注射液新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1194506184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194506184?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:48","pubTimestamp":1782391725,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司宣布，其子公司已收到国家药品监督管理局（NMPA）的通知，批准其艾瑞利布注射液增加新的适应症。这一进展标志着该药物在临床应用范围的进一步扩大，有望为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","LU0359201612.USD","BK0183","BK0239","BK0060","LU2097828474.EUR","LU2097828631.EUR","BK1191","LU1255011170.USD","LU1781817850.SGD","BK0196","LU1820825898.SGD","LU1969619763.USD","LU0405327494.USD","LU2488822045.USD","LU1023057109.AUD","600276","LU1580142542.USD","LU1064131003.USD","LU1655091616.SGD","LU1997245094.SGD","LU1997245177.USD","LU0359201885.HKD","BK0188","LU1328615791.USD","LU2289578879.USD","LU2097828805.USD","LU2328871848.SGD","LU1146622755.USD","LU0359202008.SGD","BK0012","LU2097828557.USD","LU2148510915.USD","BK0028","LU2543165471.USD","LU2097828714.EUR","LU2580892862.HKD","LU0405327148.USD","LU2495084118.USD","LU1064130708.USD","LU2580892789.USD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874269","title":"恒瑞医药：HRS-4508片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874269","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646874269?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:47","pubTimestamp":1782384420,"startTime":"0","endTime":"0","summary":"南财智讯6月25日电，恒瑞医药公告，HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXHL2600335），同意开展晚期实体瘤的临床试验。该药为新型、高效、选择性酪氨酸激酶抑制剂，拟用于乳腺癌、肺癌等适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253783217493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201885.HKD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU1023057109.AUD","LU2097828805.USD","LU2097828557.USD","BK0183","BK0239","LU1580142542.USD","BK0060","LU1655091616.SGD","LU0359202008.SGD","LU1820825898.SGD","600276","LU1146622755.USD","LU0405327494.USD","LU1781817850.SGD","LU2289578879.USD","LU1997245177.USD","LU2328871848.SGD","LU2488822045.USD","LU2495084118.USD","LU0359201612.USD","LU2097828631.EUR","LU2543165471.USD","BK0028","LU2580892862.HKD","BK1191","LU1328615791.USD","LU2097828714.EUR","01276","LU1255011170.USD","BK0188","LU1997244956.HKD","BK0196","LU2580892789.USD","LU1064130708.USD","LU2097828474.EUR","BK0012","LU2148510915.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893953","title":"智通AH统计|6月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893953","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893953?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:15","pubTimestamp":1782288906,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止6月24日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为881.82%、378.39%、334.48%；宁德时代、兆易创新、潍柴动力分列AH溢价率末三位，溢价率分别为-34.36%、-14.39%、-4.84%。其中东北电气、南华期货股份、长飞光纤光缆的偏离值位居前三，分别为199.12%、111.99%、46.64%；另外，安德利果汁、新天绿色能源、北京北辰实业股份的偏离值位居后三，分别为-25.60%、-23.78%、-21.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","EWH","LU0348788117.USD","02476","01330","01898","02691","03986","03143","01812","02359","02607","00719","03200","LU0163747925.USD","00588","00042","01108","399300","01033","03328","00553","03968","159982","03750","BK1514","LU0214875030.USD","LU0634319403.HKD","BK1171","00916","01088","LU0149721374.USD","01057","00168","06613","01081","03296","LU0516423091.SGD","LU2242644610.SGD","02465","02899","LU0244354667.USD","03678","02338","00956","06869","LU0266512473.USD","02208","00991","02218"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.032},{"period":"1month","weight":0.0954},{"period":"3month","weight":-0.1011},{"period":"6month","weight":-0.2275},{"period":"1year","weight":0.0085},{"period":"ytd","weight":-0.1592}],"compareEarnings":[{"period":"1week","weight":0.0269},{"period":"1month","weight":-0.0587},{"period":"3month","weight":-0.0925},{"period":"6month","weight":-0.1014},{"period":"1year","weight":-0.0164},{"period":"ytd","weight":-0.0832}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}